Streetbeat News

INBS

Intelligent Bio Solutions Inc.

Industry

Medical - Diagnostics & Research

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Open

1.82

Mkt cap

6.9M

Volume

180K

High

1.82

P/E Ratio

-0.26

52-wk high

11.70

Low

1.56

Div yield

N/A

52-wk low

1.00

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Among the gainers were Intelligent Bio Solutions Inc., Astra Space, Inc., and Tempest Therapeutics, Inc., which saw significant increases due to positive quarterly results and acquisition proposals. Among the losers were Enviva Inc., ContraFect Corporation, and Atara Biotherapeutics, Inc., which saw significant decreases due to poor quarterly results and disappointing clinical trial outcomes.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:13 pm

Intelligent Bio Solutions Inc. (NASDAQ:INBS) reported Q1 losses of $1.04 per share, missing the analyst consensus estimate of 64 cents by 62.5%. The company also reported quarterly sales of $109.87 thousand, missing the consensus estimate of $950 thousand by 88.43% and representing a 64.71% decrease over sales of $311.32 thousand from the same period last year. Despite this, shares of INBS are up 145% at 56 cents.

Portfolio Pulse from Erica Kollmann

November 09, 2023 | 5:46 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included Intelligent Bio Solutions (INBS), Tempest Therapeutics (TPST), Lantern Pharma (LTRN), Cyclacel Pharmaceuticals (CYCCP), Oncology Institute (TOI), and OncoCyte (OCX). Losers included Atara Biotherapeutics (ATRA), Ikena Oncology (IKNA), Acutus Medical (AFIB), Assertio Holdings (ASRT), Cardio Diagnostics Hldgs (CDIO), and BioVie (BIVI). Most of these movements were associated with the release of Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 5:31 pm

US stocks traded slightly higher with the Nasdaq Composite gaining around 50 points. Tapestry Inc reported upbeat earnings for its first quarter, beating analyst consensus. Astra Space, Intelligent Bio Solutions, and Tempest Therapeutics saw significant stock price increases following company announcements. Ikena Oncology, Atara Biotherapeutics, and Enviva Inc saw stock price drops following weak sales and disappointing results.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 5:01 pm

Shares of Intelligent Bio Solutions (INBS) are trading higher on abnormally-high volume following the release of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:56 pm

U.S. stocks traded mostly flat following the release of jobless claims data. The Dow traded down 0.02%, the NASDAQ rose 0.01%, and the S&P 500 fell 0.01%. Energy shares rose by 0.8% while health care shares fell by 1%. U.S. initial jobless claims fell by 3,000 to 217,000. Astra Space, Intelligent Bio Solutions, and Globavend Holdings saw significant increases in their shares. Tempo Automation Holdings, Atara Biotherapeutics, and Enviva saw significant decreases.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 2:43 pm

Several healthcare stocks experienced significant movement in Thursday's pre-market session. Gainers included Intelligent Bio Solutions (INBS), OncoCyte (OCX), ZyVersa Therapeutics (ZVSA), CareDx (CDNA), Lipella Pharmaceuticals (LIPO), and Alaunos Therapeutics (TCRT). Losers included Atara Biotherapeutics (ATRA), Assertio Holdings (ASRT), Akili (AKLI), Amylyx Pharma (AMLX), Kazia Therapeutics (KZIA), and Ontrak (OTRK).

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 1:06 pm

Intelligent Bio Solutions (NASDAQ:INBS) reported Q1 losses of $(1.04) per share, missing the analyst consensus estimate of $(0.64) by 62.5%. This is a 35% increase over losses from the same period last year. The company also reported quarterly sales of $109.87K, missing the analyst consensus estimate of $950.00K by 88.43%. This is a 64.71% decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 10:38 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Intelligent Bio Solutions (INBS), Ontrak (OTRK), Panbela Therapeutics (PBLA), ADMA Biologics (ADMA), LifeMD (LFMD), and AcelRx Pharmaceuticals (ACRX). Losers included Assertio Holdings (ASRT), Lucy Scientific Discovery (LSDI), Omega Therapeutics (OMGA), Cutera (CUTR), Alzamend Neuro (ALZN), and Bio-Path Hldgs (BPTH). Q3 earnings reports were released for several companies.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 9:31 pm

Intelligent Bio Solutions Inc. (NASDAQ:INBS) has announced its expansion into the New Zealand market with its Intelligent Fingerprinting Drug Screening System. The system uses fingertip sweat to screen for common drugs of abuse, offering an efficient and non-invasive alternative to traditional drug testing methods. The company's growth strategy includes further expansion throughout Asia Pacific, the United States and Canada.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.